Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a
cornerstone position in the treatment of hematological malignancies, particularly multiple …

Proteasome inhibition is a novel treatment for several hematological malignancies.
However, resistance to the proteasome inhibitor bortezomib (BTZ, Velcade) is an emerging …

Background Proteasome inhibition results in antitumor activity through various mechanisms,
including disruption of cell cycle progression and control, induction of apoptosis, and …

Proteasome inhibitors have shown relevant clinical activity in several hematological
malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient …

The ubiquitin-proteasome pathway regulates many basic cellular processes and has been
proven to be a promising target for cancer therapy. Bortezomib is the first US Food and Drug …

Inhibition of the 20S proteasome by bortezomib (Velcade) constitutes a successfully applied
therapy for blood cancer. However, emerging resistance restricts its medicinal use. For …

Since its introduction in the clinics in early 2000s, the proteasome inhibitor bortezomib (BTZ)
significantly improved the prognosis of patients with multiple myeloma (MM) and mantle cell …

Bortezomib (Velcade™) is a reversible proteasome inhibitor that is approved for the
treatment of multiple myeloma (MM). Despite its demonstrated clinical success, some …

The intracellular concentration of proteins in both normal and tumor cells are regulated by
the balance between the rates of protein synthesis vs. degradation. The ubiquitin …

The development of proteasome inhibitors (PIs) has transformed the treatment of multiple
myeloma and mantle cell lymphoma. To date, two PIs have been FDA approved, the …